Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.51 |
| ▸ | HTR5A | P47898 | 1/20 | 0.51 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072294 | 0.82 | KDM4E (0.50) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| SCHEMBL1825781 | 0.78 | HTR2A (0.46) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| SCHEMBL1456916 | 0.75 | HTR2A (0.51) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| SCHEMBL29736160 | 0.73 | HTR2A (1.00) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| SCHEMBL3045846 | 0.73 | HTR2A (1.00) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| SCHEMBL29466239 | 0.71 | TAAR1 (0.96) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| SCHEMBL169954 | 0.71 | TAAR1 (0.96) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| Hydrochloric Acid SCHEMBL2243782 | 0.70 | TAAR1 (1.00) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| Hydrochloric Acid SCHEMBL30741597 | 0.70 | TAAR1 (1.00) | HTR2CHTR2ATAAR1KDM4ENR2E1 | |
| SCHEMBL224258 | 0.69 | KDM4E (0.46) | HTR2CHTR2ATAAR1KDM4ENR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150222-A1 | IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME | MANA BIO LTD. (IL) | 2024-07-18 | — | — | WO | disclosed |
| EP-4376837-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Immunyx Pharma Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024069634-A1 | MICROTUBULE TARGETING AGENTS | Ariel Scientific Innovations Ltd. (IL) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024052923-A1 | IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME | BARCODE NANOTECH LTD. (IL) | 2024-03-14 | — | — | WO | disclosed |
| EP-4326332-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | Biond Biologics Ltd. (IL) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024033917-A1 | GRANULAR COMPOSITIONS COMPRISING A PEPTIDE AND USES THEREOF | TARSIER PHARMA LTD. (IL) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024018471-A1 | CATHEPSIN INHIBITORS AND USE THEREOF IN A METHOD FOR DETECTING AND TREATING RESISTANCE TO IMMUNOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | WO | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| WO-2009128918-A1 | COMBINATION THERAPY USING A SOLUBLE HYALURONIDASE AND A BISPHOSPHONATE | HALOZYME, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7582794-B2 | Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| WO-2009082437-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009009117-A2 | CHEMOENZYMATIC PROCESSES FOR PREPARATION OF LEVETIRACETAM | BIOVERDANT, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1699748-B1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7238835-B2 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| EP-1699748-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005061427-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | CYP2B6, CYP1B1, CYP4B1 | HTR2C 1768/4885HTR2A 2246/4885TAAR1 1981/4885 |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | HTR2C 4752/4885HTR2A 4335/4885TAAR1 3093/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | HTR2C 4528/4885HTR2A 4408/4885TAAR1 4161/4885 |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | CYP2B6, CYP1B1, CYP4B1 | HTR2C 1768/4885HTR2A 2246/4885TAAR1 1981/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | HTR2C 4559/4885HTR2A 4079/4885TAAR1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.